Appetitive Conditioning in Anorexia Nervosa (ACAN)
Appetitive Conditioning in Anorexia Nervosa: Neural, Physiological, and Behavioral Mechanisms
Anorexia nervosa (AN) is characterized by a reduced drive to pursue rewarding experiences and stimuli. Food consumption - which is almost universally experienced as pleasurable - is not described as rewarding by those with AN. This is thought to be underpinned by abnormalities around reward learning. However, the most fundamental question relating to reward in AN - whether those with AN may learn positive associations - remains unaddressed.
In this study, the investigators will identify the patterns of how those with AN acquire positive associations, how they diminish, and their relationships to physiology (heart rate and pupil responses) and brain activation. In assessing the robustness of this learning, the investigators will investigate the extent to which this association is reactivated after 24 hours, and the extent to which a memory prompt will help reinstate this previously learned positive association.
This project will allow for important advances in our understanding of the neurobiology of AN. The investigators will first identify if, and how, those with AN come to learn positive associations to cues, and secondly, the extent to which learned positive associations remain over time. Moreover, the investigators will use machine learning to ascertain whether reward learning can be predicted by physiological and neural biomarkers.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Research Analyst
- Phone Number: 32395 14165358501
- Email: anorexia.research@camh.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M6J 1H3
- Centre for Addiction and Mental Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
AN-Restricting (AN-R) Group
Inclusion criteria:
- Females from any racial or ethnic background
- Ages between 12 and 22 years
- Meet DSM-5 criteria for AN - restricting subtype
- Medically stable designated by their physician in the past month (having any of the following measurements taken by a physician or nurse within the past month preceding the telephone screen: (i) orthostasis: drop in systolic blood pressure > 20 mm Hg or diastolic blood pressure > 10 mm Hg, or an increase in heart rate (HR) > 20 bpm upon standing for 3 minutes after lying down; (ii) resting HR <45; or (iii) resting blood pressure of <80 mm Hg systolic or <50 mm Hg diastolic 99. Prospective participants who do not meet the medical instability criteria and otherwise pass the telephone screen, will be invited to proceed to the consent process. If they have not had these measurements done in the month prior, we will encourage them to visit their doctor or nurse to have these done and then to recontact us with the results ):
BP and pulse measured at the day of the scan by the investigators
- Heart rate ≥ 45 at rest
- Resting blood pressure of ≥80 mm Hg systolic and ≥50 mm Hg diastolic
- Lying and standing (after 3 min.) BP drop of ≤20 systolic and ≤10 diastolic and increase in HR ≤20 bpm
- Not taking psychiatric medications or taking serotonin-reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor medications at stable doses
History of AN-Restricting Group:
Inclusion criteria:
- Females from any racial or ethnic background
- Ages between 12 and 22 years
- EDE-Q ≤ 2 (puts them within 1 standard deviation [SD] of community norms and lower than 1 SD from clinical norms for female AN-R)
- History of AN - meeting full criteria, diagnosed by a licensed clinician
- Not taking psychiatric medications or taking serotonin-reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor medications at stable doses
- Healthy controls:
Inclusion criteria:
- Healthy females from any racial or ethnic background
- Ages 12-22 years
Exclusion Criteria:
AN-R and History of AN-R groups:
- Antipsychotic medications
- Change in dose of psychotropic medication over the previous 4 weeks
- Current psychotic disorder
Healthy controls:
- Any current Axis I disorder
- Eating Disorder Examination Questionnaire score greater than established community norms (>2)
- Met criteria for AN (in the past or present)
All:
- Neurological disorder
- Infants or children of their own
- Pregnancy
- Current risk of suicide with a plan and intent
- Ferromagnetic metal implantations or devices (electronic implants or devices, infusion pumps, aneurysm clips, metal fragments or foreign bodies, metal prostheses, joints, rods or plates)
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
AN-Restricting (AN-R)
Meet Diagnostic and Statistical Manual (DSM-5) criteria for anorexia nervosa, restricting subtype
|
The investigators will examine acquisition and extinction of learned associations to positively-valenced, socially rewarding yet symptom-neutral infant laughter sounds in an appetitive conditioning paradigm.
The investigators will also examine spontaneous recovery of this association 24 hours later when re-presented with these cues, and the reinstatement of this association when re-exposed to infant laughter.
|
|
Weight Restored AN-Restricting (WRAN-R)
|
The investigators will examine acquisition and extinction of learned associations to positively-valenced, socially rewarding yet symptom-neutral infant laughter sounds in an appetitive conditioning paradigm.
The investigators will also examine spontaneous recovery of this association 24 hours later when re-presented with these cues, and the reinstatement of this association when re-exposed to infant laughter.
|
|
Healthy controls
Healthy females from any racial or ethnic background, not meeting DSM-5 criteria for any psychiatric disorder.
|
The investigators will examine acquisition and extinction of learned associations to positively-valenced, socially rewarding yet symptom-neutral infant laughter sounds in an appetitive conditioning paradigm.
The investigators will also examine spontaneous recovery of this association 24 hours later when re-presented with these cues, and the reinstatement of this association when re-exposed to infant laughter.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Positive valence
Time Frame: Day 1
|
A 10-point Likert scale will assess self-reported pleasantness and arousal for each conditioned stimulus, and unconditioned stimulus expectancy
|
Day 1
|
|
Positive valence
Time Frame: Day 2
|
A 10-point Likert scale will assess self-reported pleasantness and arousal for each conditioned stimulus, and unconditioned stimulus expectancy
|
Day 2
|
|
Pupillary dilation
Time Frame: Day 1
|
Measured with an eye-tracking camera
|
Day 1
|
|
Pupillary dilation
Time Frame: Day 2
|
Measured with an eye-tracking camera
|
Day 2
|
|
Heart rate deceleration
Time Frame: Day 1
|
Measured with an electrocardiogram
|
Day 1
|
|
Heart rate deceleration
Time Frame: Day 2
|
Measured with an electrocardiogram
|
Day 2
|
|
Brain activation
Time Frame: Day 1
|
Neural activation in reward circuits measured with functional magnetic resonance imaging
|
Day 1
|
|
Brain activation
Time Frame: Day 2
|
Neural activation in reward circuits measured with functional magnetic resonance imaging
|
Day 2
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jamie D Feusner, M.D., Centre for Addiction and Mental Health
- Principal Investigator: Stuart Murray, Ph.D., University of Southern California
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20202201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.